Next Phase Newsletter

A venture capital firm based in the US is actively investing in life science companies. The firm primarily invests in therapeutics companies in early and growth stage. Typical check sizes are in the $25-30M range over the company’s life cycle. The firm has a preference for companies based in Los Angeles and is passionate about fostering the local life science ecosystem, but the firm is also open to investing outside of LA given that the opportunity is a great fit. Outside of LA, the firm invests almost exclusively in the US. 
 
The firm invests in therapeutics in all disease areas and modalities, and is open to both single assets and platform technologies. The firm currently has over 20 companies in their portfolio, which can be reviewed here: https://westlakebio.com/portfolio for a better sense of where the firm has invested to date.  

The firm is open to pre-clinical to early clinical stage opportunities. The firm is open to investing in promising companies even in the idea/conception stage, and has done so in the past. 
 
The firm looks for compelling technologies and is open to investing in companies founded by first-time entrepreneurs. The firm prefers to be a lead investor, and has always led Series A investments and seeks board representation when leading. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A growth and venture investor based in the U.S. typically engages in pre-clinical and Seed stage life science startups. The firm invests in companies focused on significant unmet medical needs across contract services, manufacturing, equipment, and therapeutic companies. The firm supports entrepreneurs and early-stage companies by providing deep expertise, industry knowledge, and a network of proven experts to guide them through every stage of their life cycle. 

The firm is interested in pre-clinical therapeutics, digital health, medical devices, and diagnostic companies. The firm also invests in contract services, enabling technologies, and therapeutics across cell and gene therapies, oncology, antimicrobial resistance, neurosciences, and rare diseases. While indication-agnostic, the firm has particular expertise in oncology, neurosciences, rare disease, and antimicrobial resistance. 

The firm does not have strict company or management team requirements. The firm may take a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A global, early-stage medtech venture capital firm with offices in North America and Asia has a particular focus on investing in underfunded regions globally. The firm invests in Seed and Series A rounds, with a typical check size of $250K – $1M in the form of equity. The firm will typically co-invest, and invests in 6-8 companies per year. The firm will invest globally. 
 
The firm invests in early-stage medtech companies developing life science technologies for large, unmet market needs. The firm focuses on medical devices and digital health. 
 
The firm prefers to work with experienced founders. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A Beijing-based venture capital investor with offices across China and Hong Kong manages $8 billion USD in assets and is currently overseeing multiple funds, including RMB and USD funds. The firm invests across various sectors, with life sciences and healthcare being one of the major focus areas. The firm is capable of investing from early seed to pre-IPO. For early-stage investments, the sweet spot is from Seed to Series B, with average check sizes ranging from $10 million to $20 million USD. Follow-on investments are possible. The firm is open to both leading and co-investing and will consider board or observer seats on a case-by-case basis. In terms of geographic focus, the firm primarily targets opportunities based in the United States and China. 

The firm is most interested in biotech therapeutics or drugs and is open to various modalities such as cell therapies, antibodies, small molecules, and more. The firm is open to considering different indications, with preferences for solid tumors and autoimmune diseases. It prefers assets that are close to the IND phase or, at the very least, have obtained partial proof of concept. The firm is also open to considering medical instruments but typically focuses on companies at a later stage, generating revenue or profits. 

The firm does not have specific requirements for management teams but prefers teams with strong backgrounds and successful track records. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A US-based advisory group also manages a seed fund making investments into healthcare companies. Traditionally, the firm has strong expertise in enterprise software and is most interested in healthcare companies that have a software component (such as EHR/EMR integration), monitoring technologies, and early-stage detection devices and diagnostics. The firm is also starting to explore opportunities in traditional biotech investments and drug discovery-enabling tools. The firm considers global opportunities. 

The firm is currently exploring opportunities in traditional life sciences (therapeutics, diagnostics) as well as software or technology-enabled healthcare companies. While the firm is opportunistic regarding specific technologies and disease areas, the firm generally does not invest in companies that require FDA regulatory approval. 

The firm does not have specific company or management team requirements and has no preference on leading or co-investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is an investment firm based in Shanghai, China. The firm manages 30 billion RMB and invests in fund of funds as well as direct equity investments. The firm invests across multiple sectors, with life science and healthcare being one of its primary focuses. The sweet spot starts from pre-A rounds, and the firm can invest anywhere up to pre-IPO stages. While the firm primarily focuses on opportunities in China, it is open to global opportunities, particularly those interested in soft-landing in China/Shanghai or with a China angle. The firm is open to both leading investments and co-investing. 

Within life science and healthcare, the firm is most interested in biotech therapeutics and medical technologies. For therapeutics, the firm is open to exploring various modalities (excluding mRNA) and indications such as CNS and oncology. For medical devices, the firm seeks innovative technologies, including invasive technologies, imaging devices, and brain-computer interfaces, rather than non-innovative solutions such as consumables. 

The firm does not have specific requirements for a company’s founding team but prefers companies interested in coming to Shanghai/China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A multi-stage generalist venture capital investor can write flexible check sizes typically up to $300,000 for early-stage opportunities and can participate in follow-on investments. The firm is open to global companies. 

The firm has invested in digital health, techbio, value-based healthcare, and life sciences. The firm is disease-agnostic. Notable investments in healthcare have included digital health platforms, pharmacy solutions, clinical trial innovation, and biotech companies. 

The firm does not have specific company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology